NCT01406977已完成2 期
An Open-label, Intra-patient Dose-escalation Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP).
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- The number (percent) of patients experiencing adverse events or serious adverse events
研究概览
简要总结
The purpose of the study is to determine tolerability, PK/PD and preliminary efficacy of BPS804 in adult patients with HPP treated with multiple escalating doses of BPS804.
This study will allow a comparison of several doses of the study drug within the first two weeks after administration and after a longer assessment period for the highest dose level to enable selection of dose ranges to be tested in subsequent studies in the HPP indication.
详细描述
This study was conducted and previously posted by Novartis. The record was transferred to Ultragenyx in February 2021.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female patients 18 to 60 years of age in good health (other than pre-established clinical diagnosis of HPP) as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
- •Previously established clinical diagnosis of HPP with confirmed ALPL mutation by genetic test and as manifested by:
- •Serum alkaline phosphatase levels below the age-adjusted normal range and
- •Radiologic evidence of osteopenia or osteomalacia or
- •History of plasma PLP at least twice the upper limit of normal range or
- •History of rickets, or history of premature loss of deciduous teeth, or bone deformity consistent with osteomalacia or past rickets, or past non-traumatic fracture, pseudofracture, or non-healing fracture.
- •25-(OH) vitamin D3 serum level of ≥20 ng/mL.
- •Normocalcemia with serum calcium ≥8.5 mg/dL and ≤10.2 mg/dL and normal phosphate levels (2.4 - 4.1 mg/dL) (or according to local laboratory ranges).
排除标准
- •A history of clinically significant ECG abnormalities.
- •History of malignancy of any organ system (other than localized basal cell carcinoma of the skin and for skeletal malignancies see below), within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
- •History of skeletal malignancies or bone metastases at any time.
- •History of external beam radiation to the skeleton.
- •Open epiphyses as judged by the Investigator based on previous clinical assessments.
- •Patients with suspected neural foraminal stenosis (e.g., at cervical, spinal, or lumbar site) as judged by the Investigator which could be caused by disc herniation and are described as sciatic pain, tingling, burning sensation with numbness and/or weakness.
- •History of or concomitant diseases such as hypo-/hyperparathyroidism, hypo-/hyperthyroidism, Pagets disease, previous neck surgery involving partial or complete thyroidectomy and abnormal thyroid function or thyroid disease or other endocrine disorders or conditions.
- •Treatment with any anti-resorptive medication (e.g., oral and/or injectable), bisphosphonates and/or teriparatide (e.g., ForteoTM) within the last 6 months.
- •Exposure to blood products or monoclonal antibodies within previous 12 months.
- •Any deformation of the spine (e.g., severe scoliosis, ankylosing spondylitis) or the hip which would preclude proper acquisition of lumbar spine or hip BMD by DXA.
- •Other protocol-defined inclusion/exclusion criteria may apply.
研究组 & 干预措施
BPS804 dose escalation
Experimental
BPS804 IV Setrusumab given in escalating doses from 5mg/Kg to 20mg/Kg
干预措施: BPS804 (Drug)
结局指标
主要结局
The number (percent) of patients experiencing adverse events or serious adverse events
时间窗: 141 days following initial investigational product administration
Change from baseline in primary serological bone biomarkers
时间窗: 141 days following initial investigational product administration
次要结局
- Characterization of the pharmacokinetic profile of BPS804: area under the plasma concentration-time curve (AUC)(1, 29 and 141 days following initial investigational product administration)
- Characterization of the pharmacokinetic profile of BPS804: observed maximum plasma concentration following drug administration (Cmax)(1, 15 and 29 days following initial investigational product administration)
- Characterization of the pharmacokinetic profile of BPS804: time to reach the maximum concentration (Tmax)(1, 15 and 29 days following initial investigational product administration)
- Change from baseline in secondary biomarkers(141 days following initial investigational product administration)
- The number (percent) of patients developing anti-BPS804 antibodies(141 days following initial investigational product administration)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid TumorsSolid TumorsNCT00555724Biogen40
已完成
2 期
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804Osteogenesis Imperfecta, Type IOsteogenesis Imperfecta Type IIIOsteogenesis Imperfecta Type IVNCT03118570Ultragenyx Pharmaceutical Inc112
已完成
1 期
Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma PatientsPeripheral T-cell LymphomaNCT02809573Chipscreen Biosciences, Ltd.30
终止
1 期
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell MalignanciesRichter TransformationNCT05828589BeOne Medicines51
已完成
1 期
Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)PNHNCT02598583Alexion Pharmaceuticals, Inc.13